Hansoh Pharmaceutical Group (DB:3KY) - Hisse Senedi Fiyatı, Haberler ve Analizler

3KY Stoklara Genel Bakış

3KY temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	5/6
Finansal Sağlık	5/6
Temettüler	3/6

Ödüller

Adil değer tahminimizden 40.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 2.66% oranında artması öngörülüyor

Kazançlar geçen yıl 83.1% oranında arttı

Analistler hisse senedi fiyatının 35% oranında artacağı konusunda hemfikir

Risk Analizi

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

Son 3 ayda dalgalı hisse senedi fiyatı

Hansoh Pharmaceutical Group Company Limited Rakipler

Merck KGaA

XTRA:MRK

€60.7b

Dermapharm Holding

XTRA:DMP

€1.9b

PharmaSGP Holding

XTRA:PSG

€292.6m

Sartorius

XTRA:SRT3

€13.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Hansoh Pharmaceutical Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$2.00
52 Haftanın En Yüksek Seviyesi	HK$2.66
52 Haftanın En Düşük Seviyesi	HK$1.32
Beta	0.65
11 Aylık Değişim	-22.48%
3 Aylık Değişim	-4.76%
1 Yıllık Değişim	21.95%
33 Yıllık Değişim	4.71%
5 Yıllık Değişim	-29.08%
Halka arzdan bu yana değişim	6.89%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	3KY	DE Pharmaceuticals	DE Pazar
7D	0%	-6.1%	-0.2%
1Y	22.0%	-22.4%	7.8%

Getiri vs. Endüstri: 3KY geçen yıl % -22.4 oranında getiri sağlayan German Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: 3KY geçen yıl % 7.8 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 3KY's price volatile compared to industry and market?
3KY volatility
3KY Average Weekly Movement	10.0%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.1%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 3KY hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 3KY 'nin haftalık oynaklığı ( 10% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1995	9,099	Huijuan Zhong	www.hspharm.com

Bir yatırım holding şirketi olan Hansoh Pharmaceutical Group Company Limited, Çin Halk Cumhuriyeti'nde farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Şirket, anti-tümör, anti-enfeksiyon, merkezi sinir sistemi hastalıkları, onkoloji, metabolik ve otoimmün hastalıklar vb. dahil olmak üzere terapötik alanlar için ürünler sunmaktadır.

Hansoh Pharmaceutical Group Company Limited Temel Bilgiler Özeti

Hansoh Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
3KY temel i̇stati̇sti̇kler
Piyasa değeri	€12.35b
Kazançlar(TTM)	€614.59m
Gelir(TTM)	€1.58b

20.1x

F/K Oranı

7.8x

P/S Oranı

3KY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
3KY gelir tablosu (TTM)
Gelir	CN¥12.10b
Gelir Maliyeti	CN¥1.09b
Brüt Kâr	CN¥11.01b
Diğer Giderler	CN¥6.30b
Kazançlar	CN¥4.71b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.79
Brüt Marj	91.01%
Net Kâr Marjı	38.97%
Borç/Özkaynak Oranı	0.1%

3KY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

2.3%

Mevcut Temettü Verimi

40%

Ödeme Oranı

3KY Stoklara Genel Bakış

Ödüller

Risk Analizi

Hansoh Pharmaceutical Group Company Limited Rakipler

XTRA:MRK

€60.7b

XTRA:DMP

€1.9b

XTRA:PSG

€292.6m

XTRA:SRT3

€13.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Investor sentiment deteriorates as stock falls 17%

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 22%

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Recent updates

Investor sentiment deteriorates as stock falls 17%

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 22%

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 27% undervalued

Now 21% undervalued

Upcoming dividend of HK$0.14 per share

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Now 21% undervalued

New minor risk - Dividend sustainability

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investor sentiment improves as stock rises 15%

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

New major risk - Share price stability

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Now 23% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Now 23% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Now 23% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.8% yield

Now 21% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Insufficient new directors

Now 20% undervalued after recent price drop

Full year 2022 earnings released

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share